Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 4.5% – Here’s What Happened

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) fell 4.5% on Friday . The company traded as low as $2.11 and last traded at $2.11. 13,670 shares traded hands during mid-day trading, a decline of 18% from the average session volume of 16,736 shares. The stock had previously closed at $2.21.

Alaunos Therapeutics Price Performance

The stock has a fifty day simple moving average of $2.68 and a two-hundred day simple moving average of $7.62.

Alaunos Therapeutics (NASDAQ:TCRT) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share for the quarter.

Institutional Trading of Alaunos Therapeutics

A hedge fund recently bought a new stake in Alaunos Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 15,440 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned about 0.10% of Alaunos Therapeutics as of its most recent SEC filing. Institutional investors own 27.72% of the company’s stock.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.